Trial Profile
Safety evaluation of a short-term infusion of ramucirumab for GI tract cancer patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Apr 2018
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary)
- Indications Colorectal cancer; Gastric cancer
- Focus Adverse reactions
- 02 Apr 2018 New trial record